Mein Warenkorb

HLA-A*0201 & B2M & CMV pp65

Produktanfrage

HLA-A*0201 & B2M & CMV pp65 Molekülhintergrund

Cytomegalovirus (Cytomegalovirus) is a herpes viral DNA virus. Human cytomegalovirus (HCMV) can only infect humans and multiply in humans. The antibodies. After primary infection with CMV, the body can produce specific antibodies and killer T lymphocytes to activate NM cells. The antibody has limited CMV replication ability and has a certain resistance to reinfection of the same strain, but cannot resist the activation of antibody-dependent virus and the exogenous infection of other different strains of CMV. However, specific killer T lymphocytes and antibody-dependent cytotoxic cells can exert the greatest antiviral effect. The Human HLA-A*0201 CMV (NLVPMVATV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and NLVPMVATV peptide of the CMV.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
EbselenSPI-1005; SPI-3005; PZ-51; DR-3305Phase 3 ClinicalSound Pharmaceuticals Inc, Daiichi Sankyo Co LtdTinnitus; Head and Neck Neoplasms; Diabetes Mellitus, Type 1; Ototoxicity; Diabetes Mellitus, Type 2; Coronavirus Disease 2019 (COVID-19); Small Cell Lung Carcinoma; Bipolar Disorder; Neoplasms; Hearing Loss; Coronavirus Infections; Depressive Disorder, Treatment-Resistant; Lung Neoplasms; Hearing Loss, Noise-Induced; Meniere Disease; Mental Disorders
Details
OlgotrelvirSTI1558; STI-1558Phase 3 ClinicalTexas A&M UniversityCoronavirus Disease 2019 (COVID-19)
Details
S-892216S-892216Phase 3 ClinicalShionogi & Co LtdCoronavirus Disease 2019 (COVID-19)
Details
ibuzatrelvirPF-07817883Phase 3 ClinicalPfizer IncCoronavirus Disease 2019 (COVID-19)
Details
MprosevirWPV-01Phase 3 ClinicalWestlake UniversityCoronavirus Disease 2019 (COVID-19)
Details
QLS-1128QLS-1128Phase 3 ClinicalQilu Pharmaceutical Co LtdCoronavirus Disease 2019 (COVID-19)
Details
MIR-19MIR-19Phase 3 ClinicalSt. Petersburg Scientific Research Institute of Vaccines and SeraCoronavirus Disease 2019 (COVID-19)
Details
BofutrelvirFB-2001; DC-402234Phase 3 ClinicalShanghai Institute Of Materia Medica, Chinese Academy Of SciencesCoronavirus Disease 2019 (COVID-19)
Details
SHEN-211SHEN-211; SHEN211Phase 2 ClinicalHubei JKT BioPharma Co LtdCoronavirus Disease 2019 (COVID-19)
Details
HS-10517HS-10517; HS10517Phase 2 ClinicalJiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co LtdCoronavirus Disease 2019 (COVID-19)
Details
EDP-235EDP-235Phase 2 ClinicalEnanta Pharmaceuticals IncCoronavirus Disease 2019 (COVID-19)
Details
TollovirPhase 2 ClinicalTodos Medical LtdCoronavirus Disease 2019 (COVID-19)
Details
PentarlandirSNB-01; SNB-011Phase 2 ClinicalSyneurx International (Taiwan) CorpCoronavirus Disease 2019 (COVID-19)
Details
NirmatrelvirPF-07321332Phase 2 ClinicalPfizer AsCoronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome; Hepatic Insufficiency
Details
CDI-988CDI988Phase 1 ClinicalCocrystal Pharma IncCoronavirus Disease 2019 (COVID-19)
Details
PomotrelvirPBI-0451Phase 1 ClinicalPardes Biosciences IncCoronavirus Disease 2019 (COVID-19)
Details
CMX-990CMX-990; CMX990Phase 1 ClinicalThe Scripps Research Institute IncCoronavirus Disease 2019 (COVID-19)
Details
WPV-02WPV-02; WPV02Phase 1 ClinicalWestlake Pharmaceuticals (Hangzhou) Co LtdVirus Diseases
Details
ISM-3312ISM-3312Phase 1 ClinicalInsilico Medicine LtdCoronavirus Disease 2019 (COVID-19)
Details
ABBV-903ABBV-903Phase 1 ClinicalAbbvie Inc
Details
SYH-2055SYH-2055Phase 1 ClinicalCSPC Pharmaceutical Group LtdCoronavirus Disease 2019 (COVID-19)
Details
AtilotrelvirGST-HG171Phase 1 ClinicalFujian Guangsheng Zhonglin Biotechnology Co LtdCoronavirus Disease 2019 (COVID-19)
Details
ALG-097558ALG-097558Phase 1 ClinicalRega Institute, Ku Leuven, Aligos Therapeutics IncCoronavirus Disease 2019 (COVID-19)
Details
ASC11ASC-11Phase 1 ClinicalAscletis Pharma IncCoronavirus Disease 2019 (COVID-19)
Details
LufotrelvirPF-07304814Phase 1 ClinicalPfizer IncCoronavirus Disease 2019 (COVID-19); Virus Diseases
Details
TravatrelvirTRX-01ClinicalTraws Pharma IncCoronavirus Disease 2019 (COVID-19)
Details
GS221GS-221; GS221ClinicalGrand Pharmaceutical (China) Co LtdCoronavirus Disease 2019 (COVID-19)
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Atilotrelvir/RitonavirApprovedFujian Guangsheng Zhonglin Biotechnology Co Ltd泰中定Mainland ChinaCoronavirus Disease 2019 (COVID-19)Fujian Guangsheng Zhonglin Biotechnology Co Ltd2023-11-23Coronavirus Disease 2019 (COVID-19)
Details
SimnotrelvirSIM-0417; SSD-8432; VV-934ApprovedJiangsu Simcere Pharmaceutical Co LtdMainland ChinaCoronavirus Disease 2019 (COVID-19)Jiangsu Simcere Pharmaceutical Co Ltd2023-01-28Coronavirus Disease 2019 (COVID-19)
Details
LeritrelvirRAY-1216; [14C]RAY1216; [14C]-RAY-1216ApprovedGuangdong Raynovent Biotech Co Ltd乐睿灵Mainland ChinaCoronavirus Disease 2019 (COVID-19)Guangdong Raynovent Biotech Co Ltd2023-03-23Coronavirus Disease 2019 (COVID-19); Acute Kidney Injury; Hepatic Insufficiency
Details
Simnotrelvir/RitonavirSIM-0417/Ritonavir; SSD-8432 / Ritonavir; SIM-0417 / Ritonavir; VV934 / RitonavirApprovedShanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Jiangsu Simcere Pharmaceutical Co Ltd, Wuhan Institute Of Virology, Chinese Academy Of Sciences先诺欣Mainland ChinaCoronavirus Disease 2019 (COVID-19)Jiangsu Simcere Pharmaceutical Co Ltd2023-01-28Renal Insufficiency; Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency
Details
Ensitrelvir Fumaric AcidS-217622ApprovedShionogi & Co Ltd, Hokkaido UniversityXocovaJapanCoronavirus Disease 2019 (COVID-19)Shionogi & Co Ltd2022-11-22Renal Insufficiency; Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome; Hepatic Insufficiency
Details
Nirmatrelvir/RitonavirApprovedPfizer IncPaxlovidEUCoronavirus Disease 2019 (COVID-19)Pfizer Europe Ma Eeig2022-01-28Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome
Details
  • Produktanfrage
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns